Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04619823Not ApplicableRecruiting

Virological and Immunological Determinants of Arbovirus Infection in New Caledonia

Role: collaborator

NCT04615364Recruiting

Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia

Role: collaborator

NCT05135585Not ApplicableCompleted

Evaluation of the Post-vaccination Immune Response to COVID-19 in the New Caledonian Population

Role: collaborator

NCT04328129Not ApplicableCompleted

Household Transmission Investigation Study for COVID-19 in Tropical Regions

Role: collaborator

NCT02188862Completed

Genetic Susceptibility to Rheumatic Heart Disease in the Pacific Region

Role: collaborator

All 5 trials loaded